Mistras Group, Strategy, Hyperliquid Strategies And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed as the Dow fell 150 points; Mistras surged on a $20.35/share buyout deal, while crypto and tech stocks gained.
Stocks · News reference
Alamar Biosciences Sees FY2026 Sales $116.000M-$120.000M vs $113.259M Est
Alamar Biosciences (NASDAQ:ALMR) sees FY2026 sales of $116.000 million-$120.000 million vs $113.259 million analyst estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Top 3 Health Care Stocks That May Implode In August
3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.
Stifel Maintains Buy on Alamar Biosciences, Raises Price Target to $32
Stifel analyst Daniel Arias maintains Alamar Biosciences (NASDAQ:ALMR) with a Buy and raises the price target from $28 to $32.
Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum
Alamar Biosciences expands its Alzheimer’s data partnership, adds 86,000 samples and reports Q2 sales growth of 82% year-over-year.